FDA Signals a Turning Point for Dietary Supplement Innovation

The recent FDA Dietary Supplement Innovation Public Meeting marks a pivotal moment for our industry. The agency is reexamining foundational concepts, including how dietary ingredients are defined and regulated. These discussions could ultimately lead to significant changes, potentially including revisions to DSHEA and the elimination of self-GRAS determinations.

Held at FDA’s College Park campus, the meeting drew approximately 180 in-person attendees, with an additional 700–800 participants joining virtually. The objective was straightforward: gather industry input on the FDA’s evolving concerns. Notably, senior FDA leadership was present, including Deputy Commissioner Kyle Deamentis and Cara Welch, Director of the Office of Dietary Supplements, underscoring the importance of this dialogue.

Emerging concerns: ingredient identity and transparency

A consistent theme from FDA scientists was growing concern over ingredients that are increasingly difficult to characterize. This includes:

• Substances modified through novel manufacturing techniques
• Complex botanical blends where individual components are not clearly identifiable
• Probiotics that lack sufficient strain-level identification

These challenges point to a broader issue: the current regulatory framework may not fully address the complexity of modern ingredient innovation.

Diverging industry perspectives

Industry feedback at the meeting spanned the full spectrum.

On one end, some advocacy groups argued that dietary supplements remain underregulated and raise safety concerns. On the other hand, industry organizations emphasized that existing manufacturing controls and testing ensure product safety.

Despite these differing viewpoints, there was notable alignment on one critical issue: the current New Dietary Ingredient (NDI) notification process.

A shared frustration: the NDI pathway

Across industry stakeholders, there was strong consensus that the NDI approval process is:

• Overly burdensome
• Costly
• Slow-moving

Many participants expressed concern that this process is stifling innovation rather than supporting it. As a result, major trade associations are preparing formal comments for FDA consideration.

What comes next

The FDA will now review stakeholder feedback and determine next steps. While outcomes remain uncertain, one direction seems increasingly likely: more stringent expectations around ingredient characterization, identity, and testing.

This shift would reflect the agency’s growing emphasis on scientific rigor and transparency, particularly for emerging ingredient categories.

Implications for the industry

If regulatory expectations tighten, companies will need to:

• Strengthen analytical characterization of ingredients
• Ensure traceability and identity verification, especially for complex formulations
• Align more closely with evolving FDA expectations

For organizations already investing in robust testing and scientific validation, these changes may present an opportunity rather than a challenge.

A Defining Moment for Innovation
The FDA’s actions following this meeting will help define the next era of dietary supplement regulation. While the industry continues to advocate for a balanced approach that enables innovation, one conclusion is clear: the bar for scientific substantiation and ingredient transparency is rising.

For companies prepared to meet it, the future remains full of opportunity.

Start the conversation

Have additional questions? Ready to get started? We can help.

Connect with an expert.